# Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

> **NCT04463056** · PHASE3 · COMPLETED · sponsor: **AO GENERIUM** · enrollment: 32 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria
- Marchiafava-Micheli Syndrome
- Paroxysmal Hemoglobinuria

## Interventions

- **BIOLOGICAL:** Elizaria®
- **BIOLOGICAL:** Soliris®

## Key facts

- **NCT ID:** NCT04463056
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2018-10-16
- **Final completion:** 2018-10-16
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04463056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04463056, "Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04463056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*